BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Thermo Fisher introduces VaxEvo medium for adenovirus vaccines

November 18, 2026 | News

The chemically defined medium supports HEK293 cell growth in suspension and is designed to simplify vaccine production as developers move towards manufacturing.



Thermo Fisher Scientific today introduced Gibco™ VaxEvo™ CD 293 Medium for developers of adenovirus-based vaccines for human and animal health. The medium contains no animal-derived components and is designed for use from early process development through scale-up.

In laboratory benchmarking studies, Thermo Fisher found that the new medium supported average adenovirus type 5 (Ad5) titres comparable to those achieved with selected commercial media. In some comparisons, titres reached up to 5.7 times those of the benchmark medium.

“Manufacturing readiness begins well before a process reaches the plant. The choices vaccine developers make during process development can shape how they evaluate performance, complexity and the path to scale,” said Alex Cherkassky, vice president and general manager of Thermo Fisher Scientific’s cell culture business. “We developed Gibco VaxEvo CD 293 Medium as a purpose-built starting point to help customers advance suspension-based adenovirus HEK293 processes with greater confidence.”

Thermo Fisher will offer the medium in liquid and AGT™ formats, with multiple pack sizes planned for the AGT™ range.